Document is current
Any future updates will be listed below
-
Authors
Marlet, I. R.
Andersen, R. K.
Axelsen, K. H.
Andersen, L. K.
Vissing, J.
Witting, N.
-
Funding
Funding for this research was provided by:
UCB Pharma
- License Information
-
More Information
Article History
Received: 13 June 2024
Revised: 29 September 2024
Accepted: 5 October 2024
First Online: 12 December 2024
Declarations
:
: All authors were funded by an unrestricted grant from UCB Biopharma. J. Vissing has been a consultant for Amicus Therapeutics, Arvinas, Biogen, Fulcrum Therapeutics, Genethon, Horizon Therapeutics, Lupin, ML Biopharma, Novartis Pharma AG, Regeneron, Roche, Sanofi Genzyme, Sarepta Therapeutics and UCB Pharma. He has received research, travel support and/or speaker honoraria from Alexion Pharmaceuticals, argenx, Biogen, Edgewise Therapeutics, Fulcrum Therapeutics, Lupin, Sanofi Genzyme, and UCB Pharma.
